Calcium Channel Agonists for Lambert-Eaton Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological disorders like Lambert-Eaton Myasthenic Syndrome (LEMS) are limited and often associated with severe side effects, with no effective selective calcium channel agonists available to directly address the underlying calcium channel dysfunction.
Innovation Solution
Development of calcium channel agonists with specific structures that target N- and P/Q-type calcium channels, increasing calcium flux and reducing kinase activity, which can be administered to treat conditions mediated by calcium channel dysfunction, including LEMS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatment approaches (immunosuppressants or potassium channel blockers) are used to treat LEMS, then some therapeutic effect is achieved, but severe side effects occur
Solution Approach 1:
The patent changes the fundamental parameter of treatment mechanism from indirect approaches (immunosuppressants, potassium channel blockers) to direct calcium channel agonism. The disclosed compounds directly activate calcium channels to increase calcium influx, fundamentally changing the therapeutic parameter from indirect symptom management to direct pathophysiological correction, thereby achieving effective treatment with potentially fewer side effects
Solution Approach 2:
The patent introduces calcium channel agonists as a new intermediary substance that directly mediates the therapeutic effect by binding to and activating calcium channels. This intermediary approach replaces the need for immunosuppressants or potassium channel blockers, providing a more direct and selective mechanism of action that avoids the severe side effects associated with current treatments
2Productivity
If potassium channel blockers are used to indirectly increase calcium entry, then transmitter release is enhanced, but dose-limiting side effects occur
Solution Approach 1:
The patent extracts and isolates the desired therapeutic effect (increased calcium influx through calcium channels) from the harmful mechanism (potassium channel blockade). By directly targeting calcium channels with selective agonists, the invention separates the beneficial calcium entry enhancement from the adverse effects of potassium channel inhibition, thereby achieving transmitter release enhancement without dose-limiting side effects
Solution Approach 2:
Instead of using potassium channel blockers to indirectly increase calcium entry (current approach), the patent inverts the mechanism by directly activating calcium channels with selective agonists. This inversion changes the therapeutic strategy from indirect enhancement with harmful side effects to direct activation with improved selectivity and reduced adverse effects
3Measurement precision
If selective calcium channel agonists are developed to directly target calcium channels, then treatment specificity is improved, but no such agonists have been identified to date
Solution Approach 1:
The patent segments the broad class of calcium channels into specific subtypes (N-type, P/Q-type) and develops agonists with selective affinity for these particular subtypes. This segmentation approach enables precise targeting of the specific calcium channels involved in neurotransmitter release at the neuromuscular junction, achieving high treatment specificity for LEMS while avoiding off-target effects on other calcium channel types
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The calcium channel agonists effectively restore transmitter release in LEMS models, offering a potentially more targeted and less side-effect-prone treatment option compared to existing therapies.
Implementation Method 1
Chemical communication in the nervous system is tightly regulated by the flux of calcium ions through certain subtypes of voltage-gated channels
Data Source
AI summary
Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formula I:wherein each bond depicted as “” is a single bond or a double bond as needed to satisfy valence requirements; Z1, Z2, Z3, Z4, and Z5 independently are nitrogen or carbon; R1 and R3 are alkyl; R2 is alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and R4 is alkyl or hydroxyalkyl.